Trials / Completed
CompletedNCT00632385
Efficacy and Safety of Eletriptan for the Treatment of Migraine in Patients Not Satisfied With Rizatriptan Therapy
An Open-label Study of Eletriptan for the Acute Treatment of Migraine in Migraine Sufferers Who Are Dissatisfied With Rizatriptan Therapy
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 127 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
To assess the efficacy and safety of eletriptan for migraine headaches in subjects who were not satisfied with rizatriptan therapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Eletriptan | 40 mg oral tablet for migraine attack, followed by 40 mg oral tablet if migraine reoccurred \>2 hours from first dose and within 24 hours of first dose |
Timeline
- Start date
- 2003-01-01
- Completion
- 2003-08-01
- First posted
- 2008-03-10
- Last updated
- 2021-01-27
Locations
16 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00632385. Inclusion in this directory is not an endorsement.